Lexicon Pharmaceuticals Inc Total Liabilities
Lexicon Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Lexicon Pharmaceuticals Inc (LXRX) has total liabilities worth $65.96 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check LXRX financial resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Lexicon Pharmaceuticals Inc (1999–2025)
Total liabilities of Lexicon Pharmaceuticals Inc from 1999 to 2025. This chart illustrates how Lexicon Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data.
Lexicon Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Lexicon Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanghai Amarsoft Information & Technolgy Co Ltd
SHE:300380
|
China | CN¥673.34 Million |
|
Hangzhou Pinming Software Co. Ltd. A
SHG:688109
|
China | CN¥112.42 Million |
|
Cromwell Property Group
AU:CMW
|
Australia | AU$887.80 Million |
|
IRESS LTD
F:BRF
|
Germany | €246.29 Million |
|
Shandong Yanggu Huatai Chemical Co Ltd
SHE:300121
|
China | CN¥982.97 Million |
|
COMPASS PATHW SP.ADR
F:5Y6
|
Germany | €420.03 Million |
|
Hubei Radio and Television Information Network Co Ltd
SHE:000665
|
China | CN¥6.01 Billion |
|
Indian Metals & Ferro Alloys Limited
NSE:IMFA
|
India | Rs15.90 Billion |
Liability Composition Analysis (1999–2025)
This chart breaks down Lexicon Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Lexicon Pharmaceuticals Inc asset portfolio.
Liquidity & Leverage Metrics
Lexicon Pharmaceuticals Inc Total Liabilities Ratios Explained
Lexicon Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 18.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lexicon Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lexicon Pharmaceuticals Inc (1999–2025)
The table below shows the annual total liabilities of Lexicon Pharmaceuticals Inc from 1999 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $77.45 Million | -49.20% |
| 2024-12-31 | $152.47 Million | +11.85% |
| 2023-12-31 | $136.32 Million | +76.64% |
| 2022-12-31 | $77.17 Million | +231.02% |
| 2021-12-31 | $23.31 Million | -50.83% |
| 2020-12-31 | $47.42 Million | -84.23% |
| 2019-12-31 | $300.61 Million | -3.20% |
| 2018-12-31 | $310.54 Million | -19.22% |
| 2017-12-31 | $384.44 Million | +20.81% |
| 2016-12-31 | $318.22 Million | -13.76% |
| 2015-12-31 | $368.98 Million | +96.94% |
| 2014-12-31 | $187.36 Million | +80.16% |
| 2013-12-31 | $104.00 Million | -1.05% |
| 2012-12-31 | $105.10 Million | -20.94% |
| 2011-12-31 | $132.94 Million | +10.92% |
| 2010-12-31 | $119.86 Million | +27.15% |
| 2009-12-31 | $94.26 Million | +43.52% |
| 2008-12-31 | $65.68 Million | -20.60% |
| 2007-12-31 | $82.72 Million | -21.04% |
| 2006-12-31 | $104.77 Million | -21.18% |
| 2005-12-31 | $132.91 Million | +47.05% |
| 2004-12-31 | $90.39 Million | -23.39% |
| 2003-12-31 | $117.98 Million | +270.20% |
| 2002-12-31 | $31.87 Million | +47.42% |
| 2001-12-31 | $21.62 Million | +65.47% |
| 2000-12-31 | $13.06 Million | -7.34% |
| 1999-12-31 | $14.10 Million | -- |
About Lexicon Pharmaceuticals Inc
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercialize… Read more